PHAT trades 214.3% below Wall Street's consensus target of $16.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PHAT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Phathom Pharmaceuticals, Inc. (PHAT) has a Wall Street consensus price target of $16.50, based on estimates from 9 covering analysts. With the stock currently trading at $5.25, this represents a potential upside of +214.3%. The company has a market capitalization of $419M.
Analyst price targets range from a low of $10.00 to a high of $22.00, representing a 73% spread in expectations. The median target of $15.50 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PHAT trades at a trailing P/E of -5.4x. Analysts expect EPS to grow +4.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ACADACADIA Pharmaceuticals Inc. | $3.6B | $21.23 | $30.05 | +41.5% | Buy | 34.1x | 37 |
 SUPNSupernus Pharmaceuticals, Inc. | $3.2B | $26.16 | $47.67 | +82.2% | Buy | 9.5x | 12 |
 PRGOPerrigo Company plc | $2.2B | $15.85 | $36.20 | +128.4% | Hold | 6.9x | 36 |
 IRWDIronwood Pharmaceuticals, Inc. | $723M | $4.39 | $6.68 | +52.2% | Hold | 3.6x | 30 |
 PTGXProtagonist Therapeutics, Inc. | $8.5B | $132.04 | $177.25 | +34.2% | Buy | 28.1x | 26 |
 MDGLMadrigal Pharmaceuticals, Inc. | $9.2B | $399.63 | $684.80 | +71.4% | Buy | — | 25 |
 TAKTakeda Pharmaceutical Company Limited | $66.9B | $21.02 | — | — | Buy | 0.3x | 6 |
 AZNAstraZeneca PLC | $290.8B | $186.43 | $186.67 | +0.1% | Buy | 18.2x | 41 |
 PFEPfizer Inc. | $167.5B | $29.39 | $31.13 | +5.9% | Hold | 9.8x | 40 |
 MCKMcKesson Corporation | $123.8B | $1060.84 | $983.13 | -7.3% | Buy | 23.8x | 31 |
Quick answers to the most common questions about buying PHAT stock.
The consensus Wall Street price target for PHAT is $16.5, representing 214.3% upside from the current price of $5.25. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PHAT has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $16.5 implies 214.3% upside from current levels.
PHAT's current price is $5.25 with a consensus target of $16.5 (214.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $22 for PHAT, while the most conservative target is $10. The consensus of $16.5 represents the median expectation. These targets typically reflect 12-month expectations.
PHAT is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PHAT stock forecast based on 9 Wall Street analysts shows a consensus price target of $16.5, with estimates ranging from $10 (bear case) to $22 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PHAT, with a "Buy" consensus rating and $16.5 price target (214.3% upside). 8 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PHAT analyst price targets range from $10 to $22, a 73% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.